Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | RNA helicase, putative | 0.3569 | 0.1794 | 1 |
Plasmodium falciparum | lysine-specific histone demethylase 1, putative | 0.0057 | 0.0004 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0057 | 0.0004 | 0.5 |
Entamoeba histolytica | hypothetical protein, conserved | 0.0096 | 0.0024 | 0.5 |
Brugia malayi | hypothetical protein | 0.0057 | 0.0004 | 0.0004 |
Loa Loa (eye worm) | hypothetical protein | 0.0154 | 0.0053 | 0.0053 |
Brugia malayi | Transforming growth factor beta like domain containing protein | 0.0061 | 0.0006 | 0.0006 |
Leishmania major | PIF1 helicase-like protein, putative,DNA repair and recombination protein, mitochondrial precursor, putative | 0.0096 | 0.0024 | 1 |
Plasmodium vivax | protoporphyrinogen oxidase, putative | 0.0057 | 0.0004 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0057 | 0.0004 | 0.0004 |
Plasmodium falciparum | conserved Plasmodium protein, unknown function | 0.0057 | 0.0004 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0096 | 0.0024 | 0.002 |
Mycobacterium ulcerans | oxidoreductase | 0.0057 | 0.0004 | 0.5 |
Schistosoma mansoni | Lysine-specific histone demethylase 1 | 0.0221 | 0.0088 | 0.0084 |
Toxoplasma gondii | 1,3-beta-glucan synthase component protein | 0.0256 | 0.0105 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0221 | 0.0088 | 0.0088 |
Chlamydia trachomatis | protoporphyrinogen oxidase | 0.0057 | 0.0004 | 0.5 |
Echinococcus multilocularis | lysine specific histone demethylase 1A | 0.0221 | 0.0088 | 0.0084 |
Leishmania major | PIF1 helicase-like protein, putative,DNA repair and recombination protein, mitochondrial precursor, putative | 0.0096 | 0.0024 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0239 | 0.0096 | 0.0096 |
Loa Loa (eye worm) | hypothetical protein | 0.013 | 0.0041 | 0.0041 |
Mycobacterium leprae | PROBABLE PROTOPORPHYRINOGEN OXIDASE HEMY (PROTOPORPHYRINOGEN-IX OXIDASE) (PROTOPORPHYRINOGENASE) (PPO) | 0.0057 | 0.0004 | 0.5 |
Mycobacterium tuberculosis | Possible oxidoreductase | 0.0057 | 0.0004 | 0.5 |
Mycobacterium ulcerans | protoporphyrinogen oxidase | 0.0057 | 0.0004 | 0.5 |
Echinococcus granulosus | lysine specific histone demethylase 1A | 0.0221 | 0.0088 | 0.0084 |
Giardia lamblia | Rrm3p helicase | 0.0096 | 0.0024 | 0.5 |
Trypanosoma cruzi | DNA repair and recombination helicase protein PIF7, putative | 0.0096 | 0.0024 | 1 |
Echinococcus granulosus | ATP dependent DNA helicase PIF1 | 0.0096 | 0.0024 | 0.002 |
Plasmodium falciparum | protoporphyrinogen oxidase | 0.0057 | 0.0004 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.3569 | 0.1794 | 0.1791 |
Plasmodium vivax | hypothetical protein, conserved | 0.0057 | 0.0004 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0096 | 0.0024 | 0.5 |
Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | 0.0057 | 0.0004 | 0.5 |
Loa Loa (eye worm) | bone morphogenic protein 6 | 0.0061 | 0.0006 | 0.0006 |
Echinococcus multilocularis | ATP dependent DNA helicase PIF1 | 0.0096 | 0.0024 | 0.002 |
Echinococcus multilocularis | neuropeptides capa receptor | 0.0223 | 0.0089 | 0.0085 |
Echinococcus granulosus | neuropeptides capa receptor | 0.0223 | 0.0089 | 0.0085 |
Brugia malayi | amine oxidase, flavin-containing family protein | 0.0147 | 0.005 | 0.005 |
Trypanosoma cruzi | DNA repair and recombination helicase protein PIF7, putative | 0.0096 | 0.0024 | 1 |
Schistosoma mansoni | beta-12-n-acetylglucosaminyltransferase II | 1.9669 | 1 | 1 |
Plasmodium vivax | hypothetical protein, conserved | 0.0057 | 0.0004 | 0.5 |
Mycobacterium ulcerans | dehydrogenase | 0.0057 | 0.0004 | 0.5 |
Trypanosoma cruzi | DNA repair and recombination helicase protein PIF6, putative | 0.0096 | 0.0024 | 1 |
Echinococcus granulosus | alpha 16 mannosyl glycoprotein | 1.9669 | 1 | 1 |
Onchocerca volvulus | 0.0239 | 0.0096 | 0.5 | |
Brugia malayi | SWIRM domain containing protein | 0.0239 | 0.0096 | 0.0096 |
Echinococcus granulosus | anti dorsalizing morphogenetic protein 1a | 0.0061 | 0.0006 | 0.0002 |
Plasmodium vivax | lysine-specific histone demethylase 1, putative | 0.0057 | 0.0004 | 0.5 |
Mycobacterium ulcerans | monoamine oxidase | 0.0057 | 0.0004 | 0.5 |
Mycobacterium ulcerans | flavin-containing monoamine oxidase AofH | 0.0057 | 0.0004 | 0.5 |
Echinococcus multilocularis | alpha 1,6 mannosyl glycoprotein | 1.9669 | 1 | 1 |
Schistosoma mansoni | serine-type protease inhibitor | 0.4343 | 0.2189 | 0.2186 |
Entamoeba histolytica | DNA repair and recombination protein, putative | 0.0096 | 0.0024 | 0.5 |
Echinococcus multilocularis | anti dorsalizing morphogenetic protein 1a | 0.0061 | 0.0006 | 0.0002 |
Loa Loa (eye worm) | hypothetical protein | 1.9669 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0221 | 0.0088 | 0.0088 |
Schistosoma mansoni | serine-type protease inhibitor | 0.4343 | 0.2189 | 0.2186 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 0.05 mg kg-1 | In vivo efficacy against C. albicans CY1002 5E6 cells for systemic candidiasis in mice after iv treatment on day 7 | ChEMBL. | 11392535 |
ED50 (functional) | = 5.2 mg kg-1 | In vivo efficacy against A. fumigatus CF1083 1E4 conidia/g for pulmonary aspergillosis in mice after iv treatment on day 14 | ChEMBL. | 11392535 |
IC50 (binding) | = 0.83 nM | In vitro inhibitory activity against Beta glucan synthase | ChEMBL. | 11392535 |
IC50 (functional) | = 0.27 ug ml-1 | In vitro antifungal activity of the compound against C. albicans CY1002 using 80 percent serum | ChEMBL. | 11392535 |
IC50 (functional) | = 0.37 ug ml-1 | In vitro antifungal activity of the compound against C. albicans CY1002 | ChEMBL. | 11392535 |
Observed at (functional) | = 30 ug ml-1 | Hepatotoxicity of the compound using inclusion-body formation test in hepatocytes of mice | ChEMBL. | 11392535 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.